×

Research and Markets: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/vjfzn3/familial) has announced the addition of Global Markets Direct's new report "Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2012', provides an overview of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) therapeutic pipeline. This report provides information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with latest updates, and special features on late-stage and discontinued projects.

It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). 'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).

- A review of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

For more information visit http://www.researchandmarkets.com/research/vjfzn3/familial

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Source: Research and Markets